Kodiak Sciences Inc Dossier
Qualitative Analysis
Business overview
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutics to treat high-prevalence retinal vascular diseases. The company's core technology is its proprietary Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine the high target specificity of biologics with the enhanced durability and formulation benefits of biopolymers. Its lead investigational medicine is Zenkuda (tarcocimab tedromer, KSI-301), an anti-VEGF antibody biopolymer conjugate being developed for retinal vascular diseases such as diabetic retinopathy, wet age-related macular degeneration (AMD), and retinal vein occlusion. Additionally, Kodiak is advancing its pipeline with candidates like KSI-501 (a bispecific conjugate targeting IL-6 and VEGF) and KSI-101 (developed for macular edema secondary to inflammation).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the timeline toward a multi-indication Biologics License Application (BLA) submission for Zenkuda, following positive Phase 3 topline results from the GLOW2 study in diabetic retinopathy.
Expected impact: A successful BLA submission and potential approval would transition Kodiak from a clinical-stage to a commercial-stage biopharmaceutical company.
Actively enrolling and advancing the PEAK and PINNACLE Phase 3 clinical trials for KSI-101, a novel bispecific protein targeting IL-6 and VEGF, in patients with macular edema secondary to inflammation (MESI).
Expected impact: Establishes a clinical foothold in inflammatory retinal diseases, expanding Kodiak's pipeline beyond traditional anti-VEGF therapies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Gives Kodiak Sciences access to Nona's proprietary Harbour Mice H2L2 and HCAb fully human antibody platforms to discover and develop novel multi-target therapeutic antibodies for ophthalmic diseases.
Terms: Specific financial terms for the Kodiak collaboration were not disclosed, though Nona's platform collaborations typically involve upfront payments, research funding, and downstream milestones.